Sanofi’s experimental multiple sclerosis drug tolebrutinib has encountered two major setbacks: a delayed regulatory decision in the U.S. and a failed late-stage clinical trial. The French drugmaker ...

With more than three years of experience as a personal finance writer, Jamela Adam simplifies complex money topics to help readers become experts at managing their finances. Her work has been featured ...